Other Events ·
Ocugen licenses OCU400 to Celairis for up to $7.1M plus royalties in Australia and ASEAN
OCGNOcugen, Inc.
Ocugen entered into an exclusive license agreement with Celairis Therapeutics, granting rights to commercialize its investigational gene therapy OCU400 for retinitis pigmentosa in Australia, New Zealand, and ASEAN markets. Ocugen will receive up to $7.1 million in aggregate payments, comprising an upfront fee and a milestone tied to positive Phase 3 top-line results expected in Q1 2027, plus a high-single-digit royalty on net sales and 50% of gross profits. Celairis retains regulatory and commercialization control while Ocugen maintains manufacturing rights. Ocugen is a biotechnology company developing gene therapies for blindness diseases.